Showing results (51-60 of 153) with videos related to
Sort By:
Pageof 16
Future Oncology (London, England)|July 26, 2023
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myelomaAjai Chari, Elham Askari, Jo Caers, et al.Advances in Therapy|February 21, 2020
Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic AnalysesXu Steven Xu, Philippe Moreau, Saad Z Usmani, et al.American Journal of Hematology|April 21, 2026
Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps ConferenceAjai Chari, Caitlin Costello, Amrita Krishnan, et al.Physics in Medicine and Biology|January 20, 2021
Double-strand breaks measured along a 160 MeV proton Bragg curve using a novel FIESTA-DNA probe in a cell-free environmentKristen A McConnell, Chang Chang, Annelise Giebeler, et al.Hepatology (Baltimore, Md.)|April 5, 2014
Liver transplantation in the management of porphyriaAshwani K Singal, Charles Parker, Christine Bowden, et al.American Journal of Reproductive Immunology (New York, N.Y. : 1989)|October 2, 2014
Placenta growth factor induces invasion and activates p70 during rapamycin treatment in trophoblast cellsAllison Knuth, Lawrence Liu, Halden Nielsen, et al.Blood|June 23, 2017
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myelomaAjai Chari, Attaya Suvannasankha, Joseph W Fay, et al.Journal of Immunological Sciences|March 30, 2023
Leflunomide Confers Rapid Recovery from COVID-19 and is Coupled with Temporal Immunologic ChangesAda Alice Dona, James F Sanchez, Joycelynne M Palmer, et al.Clinical Pharmacology and Therapeutics|July 24, 2025
Recommended Phase II Doses of Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma From MonumenTAL-1: Clinical Pharmacology ResultsJue Gong, Jie Zhou, Dongfen Yuan, et al.Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.Pageof 16